ClinicalTrials.gg
RecruitingNCT07071038SWIVELUpdated Feb 12, 2026

Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer Patients

A Phase 2 interventional study of Switch and Guideline Directed Intervention (GDI) in Breast Cancer, Adjuvant Treatment and Early Stage Breast Cancer, sponsored by Dartmouth-Hitchcock Medical Center. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-12.

Sponsored by Dartmouth-Hitchcock Medical Center · Phase 2, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Breast Neoplasms by Dartmouth-Hitchcock Medical Center — 6 open to participants now, 8 under way, none of them phase 3. Breast Neoplasms · Dartmouth-Hitchcock Medical Center.

Planned enrollment
9th of 34
62 · median 30
Started
2025
with 2 others
Phase 2
6 of 44
2 open now
Registered
42nd of 44
by date

Among the 44 studies in Breast Neoplasms by Dartmouth-Hitchcock Medical Center, this one is the 9th largest by planned enrollment of the 34 interventional ones that give a count, is one of 3 that started in 2025, is one of 6 in phase 2, and was the 42nd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

6 of the 44 studies in Breast Neoplasms by Dartmouth-Hitchcock Medical Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Breast Neoplasms by Dartmouth-Hitchcock Medical Center, or all of them as a file.
02

Study summary

Researchers have learned that about 50% of women do not finish the standard 5-year breast cancer treatment with an aromatase inhibitor. An aromatase inhibitor is hormone therapy that lowers the chance of breast cancer coming back (recurring) after surgery by blocking an enzyme in fat tissue called aromatase; aromatase changes other hormones in the body to estrogen. Women who do not complete the standard 5-year treatment are at higher risk of their cancer coming back. The goal of this research is to prevent breast cancer from coming back after surgery by helping women to stay on treatment with aromatase inhibitors. Researchers believe the best path to help women to stay on treatment is to create a better way to manage (control) side effects.

Read the detailed description

This is a two-arm, randomized-controlled trial with option for cross-over that compares the effectiveness of a 'switch' in hormonal therapy to guideline-directed intervention (GDI) for frontline management of side effects of aromatase inhibitors among breast cancer patients. Researchers plan to enroll post-menopausal patients with breast cancer who receive a first-time prescription for an aromatase inhibitor (AI). The anticipated enrollment is 124 participants to meet the goal of 62 evaluable participants.

Baseline symptom burden and quality of life will be assessed by validated surveys prior to starting AI. After starting AI, participants will be contacted at 2 weeks, and then every 4-weeks to screen for the development of bothersome side effects using a validated screening tool. The screening tool (FACIT GP5) is a single-item questionnaire that asks participants to respond to the following: "I am bothered by side effects of treatment," with answers ranging from 'Not at all' (score 0) to 'Very much' (score 4). Participants who score either a 3 or 4 on the FACIT GP5 will be considered to have a positive screening result. They will be randomized 1:1 to either receiving a different AI ('switch') or guideline-directed intervention (GDI). A 'GDI Book' was created for this study and will serve as a reference for selecting GDI treatment.

Participants who continue to have symptoms despite completing two lines of treatment within their assigned arm will be allowed to cross-over to the other treatment arm. Patients who are otherwise doing well in their treatment arm may stay in that treatment arm for the duration of the study. Cross-over is entirely optional.

Participants who do not develop side effects will continue to be monitored on study for up to 6 months. Participants with side effects that do not meet criteria for randomization (FACIT GP5 scores of 1 or 2) will receive standard of care at the discretion their treating provider.

Urine samples will be collected as a part of this study, to assess for adherence to endocrine therapy at the time of randomization, and at 3, 6 12 and 24 months after randomization. For participants that are not randomized, urine will be collected at 6, 12 and 24 months only. Urine samples will be collected during routine office visits when possible. Urine test results will remain anonymous (the treating provider will not know the results).

03

Conditions studied

  • Breast Cancer
  • Adjuvant Treatment
  • Early Stage Breast Cancer

Browse trials for

Keywords

  • breast cancer surgery
  • aromatase inhibitor
  • aromatase side effects
  • hormone therapy
  • quality of life
  • adherence
  • early breast cancer
  • switching medications
  • hormonal therapy
  • letrozole
  • anastrozole
  • exemestane
  • tamoxifen
  • adjuvant therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histologic documentation of DCIS or invasive breast cancer by core needle or incisional .
  • The DCIS or invasive cancer must be estrogen receptor alpha (ER)-positive
  • The invasive cancer must be -negative (IHC 0-1+, or with a FISH ratio of \<1.8 if IHC is 2+ or if IHC has not been done)
  • Clinical Stage I-III invasive breast cancer or DCIS
  • Patients for whom treatment with one of the following would be clinically indicated: letrozole, anastrozole, exemestane
  • Patients who anticipate continuing with adjuvant endocrine therapy for a minimum of 2 years at the time of registration
  • Women over 18 years of age who are , defined as last menstrual period >2 years prior to registration, or >1 year prior to registration with FSH and estradiol in post-menopausal range.
  • Patients must meet the following clinical laboratory criteria:

    • (ANC) >1,000/mm3 and count > 75,000/mm3
    • Total \<1.5 x the (ULN).
    • (ALT) and aspartate aminotransferase (AST) \< 3 x ULN.
  • Ability to give .

Exclusion criteria

Exclusion Criteria:

  • Prior endocrine therapy for any -confirmed cancer or prevention of breast cancer in the last 10 years is not allowed.
  • Any other therapy for breast cancer. Exception: Bisphosphonate or denosumab treatment for metabolic bone issues are allowed.
  • Patients who are prescribed tamoxifen as the first endocrine therapy rather than an aromatase inhibitor.
  • Women who are pregnant or lactating.
  • Prisoners.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
62 participants (estimated)

Study arms

  • Active comparator
    Switch

    Participants (people taking part in this study) enrolled to this study will receive treatment with the aromatase inhibitor (AI) Letrozole and fill out surveys to check for side effects to see how the side effects are making their daily life harder. If side effects are reported, the Participant will be randomized (placed by chance) to a group where they will receive either a different AI ('switch') or receive guideline directed intervention "GDI" using medication and non-medication treatment options.

    Drug: Switch

  • Active comparator
    Guideline Directed Intervention (GDI)

    Participants will receive evidence-based (proven to work) treatment options for side effects according to national guidelines; these may include medications or non-medication options (guideline-directed interventions, GDIs).

    Other: Guideline Directed Intervention (GDI)

Interventions

  • DrugSwitch

    Participants in the switch arm will receive a new prescription for either anastrozole or exemestane at a dose of 1mg or 25mg daily, respectively. The choice of AI in the first line setting will be at the discretion of the treating oncologist. If side effects persist after the 1st line switch, the participant will have the option to switch to another AI not yet tried, or to tamoxifen at 20mg daily

  • OtherGuideline Directed Intervention (GDI)

    Subjects in this group will receive a guideline-directed intervention "GDI" using medication and/or non-medication treatment options according to the National Comprehensive Cancer Network (NCCN) supportive care guidelines. A GDI Book was created for this trial that lists treatment options and resources for each of the common side effects of hormonal therapy and is available for providers and staff to help select treatment options. For less common side effects with limited evidence-based options, treatment will be determined in collaboration with the treating provider and PI, using best available evidence.

This study also gives AnastrozoleStudies of AnastrozoleAnastrozole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., ExemestaneStudies of ExemestaneExemestane pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Change in Endocrine Symptom Burden at 3 months

    The primary outcome of this study is the change in the Functional Assessment of Cancer Therapy Endocrine Subscale (FACT-ES) endocrine symptom subscale (ESS-23) survey score as measured from the time of randomization to 3 months, or at the time of cross-over or discontinuation of AI due to intolerable side effects, whichever comes first. The ESS-23 score ranges from 0-92, with lower scores indicating higher symptom burden.

    Time frame: 3 months after randomization

Secondary outcomes

  1. Change in Symptom Burden at 3 and 6 months (FACT-ES)

    Change in FACT-ES Endocrine Subscale survey scores from time to randomization to 3-months and at 6 months, after allowing for cross-over in an intention to treat analysis

    Time frame: 3 and 6 months after randomization

  2. Change in Symptom Burden at 3 and 6 months (PROMIS)

    Change in Patient-Reported Outcomes Measurement Information System (PROMIS) survey scores (fatigue, depression, anxiety, pain, sleep disturbance, physical function) from baseline to 3 and 6 months in an intention to treat analysis. Each PROMIS short form symptom survey consists of 8 items, and raw scores are converted to T-scores ranging from 0-100 with associated standard errors based on the general US population. Higher T scores correspond to more symptom burden. The change in average T scores for relevant symptom surveys will be compared between groups.

    Time frame: 3 and 6 months

  3. Change in Symptom Burden at 3 and 6 Months (FSFI)

    Change in Female Sexual Function Index (FSFI) survey score from baseline to 3 and 6 months in an intention to treat analysis. The FSFI is a 19-item validated survey, answers are given on a 5-point Likert scale and questions are weighted to give a total score ranging from 2-36, with higher scores indicating better sexual function.

    Time frame: 3 and 6 months

  4. Quality of life at 3 and 6 months

    Change in the Functional Assessment of Cancer Therapy-General (FACT-G) survey score from time to randomization to 3- and 6-months. The FACT-G measures physical, social, emotional and function well-being, with a total of 27 items that are answered on a 5-point Likert scale. Total scores range from 0-108, with higher scores indicating better quality of life.

    Time frame: 3 and 6 months after randomization

  5. Adherence to Endocrine Therapy at 3 and 6 months

    Adherence to endocrine therapy will be assessed by urine testing and corroborated by VOILS survey and pharmacy records. The VOILS Adherence scale assesses patient-reported extent and reasons for nonadherence. Answers are given on a 5-point Likert scale, with higher scores indicating a greater degree of non-adherence.

    Time frame: 3 and 6 months after randomization

  6. Long-Term Adherence to Endocrine Therapy at 12 and 24 months

    Long-term adherence to endocrine therapy will be assessed by urine testing and corroborated by VOILS survey and pharmacy records.

    Time frame: 12 and 24 months after randomization

  7. Factors Associated with Adherence to Endocrine Therapy

    Patient-perceived self-efficacy, illness perception and hopefulness will be evaluated using validated surveys at the time of enrollment. Those survey scores will be assessed for associations with long-term adherence to endocrine therapy.

    Time frame: 2 years after randomization

  8. Distant Disease-Free Survival at 1, 2 and 5 Years

    Distant disease-free survival will be assessed by chart review at 1, 2, and 5 years after randomization.

    Time frame: 5 years after randomization

Other outcomes

  1. TSQM Screening Tool

    A modified version of the Treatment Satisfaction Questionnaire for Medication (TSQM) will be assessed as a screening tool to identify patients who are having clinically meaningful side effects requiring intervention.

    Time frame: 2 years after enrollment

  2. Responder Thresholds to Define Clinically Meaningful Change in Symptoms

    Symptom surveys have classically been assessed over time using the 'minimally important difference' (MID) to define clinically meaningful results. This exploratory objective will test the sensitivity of a predefined 'responder threshold' (score change) to identify participants with clinically meaningful improvement in symptoms, according to recent FDA recommendations.

    Time frame: 3 and 6 months after randomization

  3. Disparities and Access to Care

    Patient perceived barriers to the use of evidence-based interventions will be assessed by exit survey.

    Time frame: 6 months after randomization

07

Study locations

1 of 1 sites recruiting
  • Dartmouth Cancer Center
    Lebanon, New Hampshire 03756, United States
    Recruiting
    • Elaine P Kuhn, MD, MS · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Aug 2026, 9 months after the start.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 9 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2025
First posted
Jul 17, 2025
StartActual
Oct 17, 2025
Primary completionEst.
Aug 5, 2026
CompletionEst.
Aug 5, 2027
Last update
Feb 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07071038
Responsible party
Elaine.P.Kuhn (Principal Investigator, Dartmouth-Hitchcock Medical Center) — Principal investigator
First posted
Jul 17, 2025
Start date
Oct 17, 2025
Primary completion
Aug 5, 2026 (estimated)
Completion
Aug 5, 2027 (estimated)
Last update
Feb 12, 2026

Study contacts

Kristina M. Willey
Contact
Kristina.M.Willey@hitchcock.org
603-650-7705

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Anastrozole · Exemestane

Start the discussion